Nuvectis Pharma Files 8-K

Ticker: NVCT · Form: 8-K · Filed: May 9, 2025 · CIK: 1875558

Nuvectis Pharma, Inc. 8-K Filing Summary
FieldDetail
CompanyNuvectis Pharma, Inc. (NVCT)
Form Type8-K
Filed DateMay 9, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: disclosure, sec-filing

TL;DR

Nuvectis Pharma filed a standard 8-K, no major news yet.

AI Summary

Nuvectis Pharma, Inc. filed an 8-K on May 9, 2025, reporting other events and financial statements. The filing does not contain specific details on new events, material agreements, or financial results, but serves as a standard disclosure.

Why It Matters

This 8-K filing indicates Nuvectis Pharma, Inc. is making a required disclosure to the SEC, which could contain updates on corporate events or financial status.

Risk Assessment

Risk Level: low — The filing is a routine 8-K disclosure without specific material events detailed, suggesting no immediate significant risk or opportunity.

Key Players & Entities

  • Nuvectis Pharma, Inc. (company) — Registrant
  • May 9, 2025 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of Incorporation
  • 001-41264 (identifier) — SEC File Number
  • 86-2405608 (identifier) — IRS Employer Identification No.
  • 1 Bridge Plaza Suite 275 Fort Lee, NJ 07024 (address) — Principal Executive Offices
  • ( 201 ) 614-3150 (phone_number) — Registrant's telephone number

FAQ

What is the primary purpose of this 8-K filing for Nuvectis Pharma, Inc.?

The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of May 9, 2025.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on May 9, 2025.

In which state is Nuvectis Pharma, Inc. incorporated?

Nuvectis Pharma, Inc. is incorporated in Delaware.

What is the SEC file number for Nuvectis Pharma, Inc.?

The SEC file number for Nuvectis Pharma, Inc. is 001-41264.

What is the principal executive office address for Nuvectis Pharma, Inc.?

The principal executive office address for Nuvectis Pharma, Inc. is 1 Bridge Plaza Suite 275, Fort Lee, NJ 07024.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 9, 2025 regarding Nuvectis Pharma, Inc. (NVCT).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.